Drug Discovery for Protozoan Parasites

产品说明： 本申请请求支持由Norman C.沃茨放大图片作者：Vicky M.艾弗里，将于2012年1月15日至20日在新墨西哥州圣达菲举行。全世界每年有数亿人感染原虫。与这些疾病相关的死亡率和发病率预计将增加，由于抗药性寄生虫的发展，缺乏足够的疫苗，以及药物开发管道中抗原生动物剂的短缺。了解发病机制;寄生虫的生长和分化机制以及代谢过程的研究为鉴定疟疾、利什曼病和锥虫病的新型药物靶标提供了新的见解和挑战。将靶标鉴定和验证与结构生物学、遗传操作和高通量高内容筛选平台的进展相结合的综合策略可能会加速抗原生动物药物的开发。这次会议是唯一一次讨论治疗和预防寄生虫感染药物开发的国际会议。它将汇集来自学术界、政府和工业界的寄生虫学家、化学家、药理学家和临床医生，讨论新的抗原生动物化学型的发展和先导化合物进入临床开发的机会。跨学科互动的机会将大大提高真菌病原体的同期会议：从基础生物学到药物发现，这将与本次会议分享一个主旨演讲和两个全体会议。 公共卫生相关性： 原生动物寄生虫感染被广泛认为是“被忽视的疾病”。“在发展中世界的许多地方，日益恶化的卫生保健系统、药品不足、缺乏有效疫苗、耐药性、内乱、经济困难和气候变化预计将导致原生动物寄生虫死亡人数增加。Keystone Symposia原生动物寄生虫药物发现会议是唯一一次讨论药物开发以治疗和预防寄生虫感染的国际会议。它将汇集来自学术界、政府和工业界的寄生虫学家、化学家、药理学家和临床医生，讨论新型抗原生动物化学型的发展以及先导化合物进入临床开发的机会。

DESCRIPTION: This application requests support for a Keystone Symposia meeting entitled Drug Discovery for Protozoan Parasites, organized by Norman C. Waters, Frederick S. Buckner and Vicky M. Avery, which will be held in Santa Fe, New Mexico from January 15 - 20, 2012. Hundreds of millions of people world-wide are infected each year with protozoan parasites. The mortality and morbidity associated with these diseases are expected to increase due to the development of drug resistant parasites, the absence of adequate vaccines, and a shortage of anti-protozoan agents in the drug development pipelines. Understanding the pathogenesis; mechanisms of growth and differentiation; and metabolic processes of the parasites has provided new insights and challenges in the identification of novel drug targets for malaria, leishmaniasis, and trypanosomiasis. Integrated strategies combining target identification and validation with advances in structural biology, genetic manipulations and high-throughput high-content screening platforms are likely to accelerate the development of anti-protozoan drugs. This meeting is the only international meeting that addresses the development of drugs to treat and prevent parasite infections. It will bring together parasitologists, chemists, pharmacologists and clinicians from academia, government and industry to discuss opportunities for the advancement of novel anti-protozoan chemotypes and progression of lead compounds into clinical development. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Fungal Pathogens: From Basic Biology to Drug Discovery, which will share a keynote address and two plenary sessions with this meeting. PUBLIC HEALTH RELEVANCE: Infections due to protozoan parasites are widely regarded as "neglected diseases." In many parts of the developing world, deteriorating health care systems, inadequate medicines, lack of effective vaccines, drug resistance, civil unrest, economical hardship, and climate change are expected to lead to increases in deaths from protozoan parasites. The Keystone Symposia meeting on Drug Discovery for Protozoan Parasites is the only international meeting that addresses the development of drugs to treat and prevent parasite infections. It will bring together parasitologists, chemists, pharmacologists and clinicians from academia, government and industry to discuss opportunities for the advancement of novel anti-protozoan chemotypes and progression of lead compounds into clinical development.